Molecular therapy for safeguarding your heart against cardiac dysfunction: Rebamipide (Trade names: Mucosta, Rebagen, and Rebagit) , a gastrointestinal medication used in the treatment of gastroduodenal ulcers, and gastritis, decreases tumor suppressor Mir-128 and cyclin-dependent kinase inhibitor p27 expression, increases SUZ12 expression, increases Cyclin E and CDK2 expression, promotes proliferation/re-entry of postnatal/adult cardiomyocytes, attenuates fibrosis, ameliorates cardiac dysfunction, and promotes heart repair in response to myocardial infarction, via up-regulation of its target gene, 3/February/2019, 11.10 pm

Combinatorial therapy for drug-resistant cancers: A therapeutic mix encompassing Metformin and Navitoclax (ABT-263) (MAN) inhibits the expression of phospholipid glutathione peroxidase (GPX4), inhibits GPX4 signaling network and lipid peroxidase pathway, suppresses EMT protein ZEB1, increases sensitivity to anticancer therapy and prolongs survival via upregulation of its target gene, 3/February/2019, 10.58 pm
February 3, 2019
Combinatorial therapy for gynecologic cancers: A therapeutic mix encompassing Metformin and Navitoclax (ABT-263) (MAN) inhibits the expression of HDAC6, acetylates tumor suppressor proteins, activates tumor suppressor function, and stifles the progression of ARID1A-mutated ovarian cancers, via up-regulation of its target gene, 3/February/2019, 11.22 pm
February 3, 2019
Show all

Introduction: What they say:

A recent study from Department of Pathology and Laboratory Medicine, University of Cincinnati College of Medicine, Cincinnati, OH, 45267, USA; Key Laboratory of Molecular Target and Clinical Pharmacology, School of Pharmaceutical Sciences & Fifth Affiliated Hospital, Guangzhou Medical University, Guangzhou, Guangdong, 511436, China; and Department of Pathology and Laboratory Medicine, University of Cincinnati College of Medicine, Cincinnati, OH, 45267, USA shows that “Loss of microRNA-128 promotes cardiomyocyte proliferation and heart regeneration.” This study was published, in the 16 Feb 2018 issue of Nature communications (one of the best journals in science with an impact factor of 12+), by Prof Wang Y, Huang W, and others.


What we say:

On the foundation of this interesting finding, Dr L Boominathan PhD, Director-cum-chief Scientist of GBMD, reports that: Molecular therapy for safeguarding your heart against cardiac dysfunction: Rebamipide (Trade names: Mucosta, Rebagen, and Rebagit, a gastrointestinal medication used in the treatment of gastroduodenal ulcers, and gastritis, decreases tumor suppressor Mir-128 and cyclin-dependent kinase inhibitor p27 expression, increases SUZ12 expression, increases Cyclin E and CDK2 expression, promotes proliferation/re-entry of postnatal/adult cardiomyocytes, attenuates fibrosis, ameliorates cardiac dysfunction, and promotes heart repair in response to myocardial infarction, via up-regulation of its target gene


From the significance of the study to public health relevance:

Given that: (1) cardiovascular disease is the leading cause of death worldwide; (2) the raise of death rate, due to cardiovascular disease, has increased from 123 lakhs in 1990 to 173 lakhs in 2013; (3) 85% of people over 80 years are susceptible to cardiovascular diseases;(4) in India, in 2004, 14.6 lakhs deaths (14% of total deaths) were due to ischemic heart disease; (3) the death due to cardiovascular disease is higher in low-to-middle income countries compared to developed countries; (4) the global economic cost spent in the treatment of cardiovascular disease in 2011 was little more than 10 billion US dollars; (5) an alarming number of people, such as 230 lakhs people, will die from cardiovascular diseases each year by 2030, there is an urgent need to find: (i) a way to induce regeneration of cardiomyocytes that were lost in Myocardial patients; (ii) a cheaper alternative to the existing expensive drugs; and (iv) a side-effect-free Natural product-based drug.


What is known?

Prof Wang’s research team has shown recently that: (1) miRNA-128 is upregulated in terminally differentiated cardiomyocytes (CMs); (2) Overexpression of MiR-128 in cardiomyocytes inhibits cardiomyocyte proliferation and function; (3) Deletion of miR-128 in postnatal cardiomyocytes increase proliferation by increasing the expression of DNA modifying protein SUZ12; (4) Increased expression of Suz12 inhibits the expression of cyclin-dependent kinase inhibitor p27; (5) Down-regulation of p27 results in increased expression of the positive regulators of cell cycle, such as Cyclin E and CDK2; and (6) Deletion of Mir-128: (a) drives adult cardiomyocytes to re-enter into cell cycle; (b) attenuates fibrosis; and (c) suppresses cardiac dysfunction in response to myocardial infarction, suggesting that inhibition of miR-128 expression may promote cardiomyocyte proliferation and heart regeneration.


From research findings to therapeutic opportunity:

This study suggests, for the first time, that Rebamipide may promote heart regeneration and repair. Rebamipide, by increasing the expression of its target genes, it may decrease the expression of miRNA-128 (fig.1). Thereby, it may: (1) increase the expression of Suz12;(2) decrease the expression of CDK inhibitor p27; (3) increase the expression of gene products that promote cardiac proliferation, including Cyclin E and CDK2;(4) increase the expression of miRNAs that promote cardiac regeneration;(5) increase cardiomyocyte proliferation; (6) suppress fibrosis; (7) promote cardiomyocyte survival/regeneration; (8) promote recovery after myocardial infarction; and (9) extend lifespan (fig 1).

Figure 1.  Mechanistic insights into how Rebamipide decreases the expression of MiR-128, and CDKI p27,  increases the expression of Cyclin E and CDK2 and regulates the expression of other genes that promote cardiac repair and regeneration

Figure 2. Rebamipide functions as a Cardioprotective agent. Sofalcone, through induction of  MiR-128, CDKI p27 and down-regulation of Cyclin E and CDK2, may function as a cardioprotective agent.

[easy_payment currency=”USD”]

Thus, Candesartan may preserve myocardial function after myocardial infarction and prevent aging-associated (or, stress-associated) decline in cardiac function. Together, this study suggests that Rebamipide or its analogs, either alone or in combination with other cardioprotective drugs,” may heal damaged cardiac tissue; and regenerate new cardiomyocytes after myocardial infarction (fig.2).


Details of the research findings:

Idea Proposed/Formulated (with experimental evidence) by:

Dr L Boominathan Ph.D.

Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/

Undisclosed mechanistic information: How does Rebamipide decrease the expression of MiR-128 and p27?

Amount: $ 500 #

# Research cooperation

For purchase and payment details, you may reach us at admin@genomediscovery.org


References:

Web:http://genomediscovery.org or http://newbioideas.com/

Citation: Boominathan, L., Molecular therapy for safeguarding your heart against cardiac dysfunction: Rebamipide (Trade names: Mucosta, Rebagen, and Rebagit, a gastrointestinal medication used in the treatment of  gastroduodenal ulcers, and gastritis, decreases tumor suppressor Mir-128 and cyclin-dependent kinase inhibitor p27 expression, increases SUZ12 expression, increases Cyclin E and CDK2 expression, promotes proliferation/re-entry of postnatal/adult cardiomyocytes, attenuates fibrosis, ameliorates cardiac dysfunction, and promotes heart repair in response to myocardial infarction, via up-regulation of its target gene, 3/February/2019, 11.10 pm, Genome-2-Biomedicine Discovery center (GBMD), http://genomediscovery.org

Courtesy: When you cite drop us a line at admin@genomediscovery.org

 

Comments are closed.